BRPI0609741A8 - composto, método de preparação e uso do mesmo, composição farmacêutica, e ,método para tratar distúrbios mentais em um mamífero. - Google Patents
composto, método de preparação e uso do mesmo, composição farmacêutica, e ,método para tratar distúrbios mentais em um mamífero.Info
- Publication number
- BRPI0609741A8 BRPI0609741A8 BRPI0609741A BRPI0609741A BRPI0609741A8 BR PI0609741 A8 BRPI0609741 A8 BR PI0609741A8 BR PI0609741 A BRPI0609741 A BR PI0609741A BR PI0609741 A BRPI0609741 A BR PI0609741A BR PI0609741 A8 BRPI0609741 A8 BR PI0609741A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparation
- pharmaceutical composition
- mammal
- mental disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
composto, método de preparação e uso do mesmo, e, composição farmacêutica. a invenção refere-se a uma forma cristalina ortorrômbica de composto (z)-2-butenodioato de trans-5-cloro-2,3 ,3 a, 1 2b-tetraidro-2-metil- 1h-dibenz[2,3 :6,7]oxepino[4,5-c]pirrol, aos métodos para a preparação desta forma de cristal e às composições farmacêuticas compreendendo uma forma cristalina ortorrômbica.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05102742.3 | 2005-04-07 | ||
EP05102742 | 2005-04-07 | ||
EP05102969 | 2005-04-14 | ||
EP05102969.2 | 2005-04-14 | ||
PCT/EP2006/061408 WO2006106135A1 (en) | 2005-04-07 | 2006-04-06 | Crystal form of asenapine maleate |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0609741A2 BRPI0609741A2 (pt) | 2010-04-27 |
BRPI0609741A8 true BRPI0609741A8 (pt) | 2018-03-13 |
Family
ID=36617328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0609741A BRPI0609741A8 (pt) | 2005-04-07 | 2006-04-06 | composto, método de preparação e uso do mesmo, composição farmacêutica, e ,método para tratar distúrbios mentais em um mamífero. |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP1917267B1 (pt) |
JP (1) | JP5058151B2 (pt) |
KR (1) | KR101422843B1 (pt) |
AR (1) | AR056306A1 (pt) |
AT (2) | ATE418556T1 (pt) |
AU (1) | AU2006231617B2 (pt) |
BR (1) | BRPI0609741A8 (pt) |
CA (1) | CA2603509C (pt) |
CY (2) | CY1106902T1 (pt) |
DE (2) | DE602006000080T2 (pt) |
DK (2) | DK1710245T3 (pt) |
DO (1) | DOP2006000082A (pt) |
ES (2) | ES2318742T3 (pt) |
GT (1) | GT200600135A (pt) |
HN (1) | HN2006014095A (pt) |
HR (1) | HRP20070429T3 (pt) |
IL (1) | IL186355A (pt) |
MX (1) | MX2007012445A (pt) |
MY (1) | MY137969A (pt) |
NO (1) | NO340520B1 (pt) |
NZ (1) | NZ562124A (pt) |
PE (1) | PE20061311A1 (pt) |
PL (2) | PL1917267T3 (pt) |
PT (2) | PT1917267E (pt) |
RS (1) | RS50532B (pt) |
RU (1) | RU2405786C2 (pt) |
SI (2) | SI1917267T1 (pt) |
SV (1) | SV2006002473A (pt) |
TW (1) | TWI364423B (pt) |
UY (1) | UY29459A1 (pt) |
WO (1) | WO2006106135A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2007002891A1 (es) * | 2006-10-06 | 2008-04-18 | Organon Nv | Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e |
TW201113018A (en) * | 2009-06-24 | 2011-04-16 | Organon Nv | Injectable formulations containing asenapine and method of treatment using same |
US8779161B2 (en) | 2010-06-18 | 2014-07-15 | Dr. Reddy's Laboratories Limited | Asenapine maleate |
WO2012066565A2 (en) * | 2010-11-16 | 2012-05-24 | Cadila Healthcare Limited | Asenapine maleate amorphous and crystalline form and process for preparation thereof |
EP2468750A1 (en) | 2010-12-13 | 2012-06-27 | Chemo Ibérica, S.A. | Polymorphic forms of asenapine maleate and processes for their preparation |
WO2012123325A1 (en) | 2011-03-11 | 2012-09-20 | Medichem S.A. | NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID |
ITMI20110734A1 (it) * | 2011-05-02 | 2012-11-03 | Olon Spa | Sali cristallini di asenapina |
EP2524920A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Asenapine Hydrochloride Salt Forms |
EP2524919A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids |
EP2524921A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Salts of Asenapine |
US9505771B2 (en) | 2011-05-18 | 2016-11-29 | Laboratories Lesvi S.L. | Stable micronised monoclin form of asenapine maleate and its synthesis |
WO2012156676A1 (en) | 2011-05-18 | 2012-11-22 | Laboratorios Lesvi S.L. | Monoclinic crystalline form of asenapine maleate with a specific particle size distribution |
WO2013041604A1 (en) | 2011-09-21 | 2013-03-28 | Sandoz Ag | Crystal form of asenapine maleate |
EP2572703A1 (en) | 2011-09-21 | 2013-03-27 | Hexal AG | Compressed oral dosage form for asenapine maleate |
KR102013476B1 (ko) * | 2012-07-26 | 2019-08-22 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 및 그 제조 방법 |
ITMI20121810A1 (it) | 2012-10-24 | 2014-04-25 | Chemo Iberica Sa | Poliformi di maleato di asenapina e processo per la loro preparazione |
US9597291B2 (en) | 2012-12-11 | 2017-03-21 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
WO2014127786A1 (en) | 2013-02-22 | 2014-08-28 | Zentiva, K.S. | Orally disintegrating pharmaceutical composition comprising asenapine |
US10786520B2 (en) | 2015-09-02 | 2020-09-29 | Eloxx Pharmaceuticals Ltd. | Aminoglycoside derivatives and uses thereof in treating genetic disorders |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
EP3558276A1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
WO2019243452A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
HU225051B1 (en) * | 1994-03-02 | 2006-05-29 | Organon Ireland Ltd | Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
WO1999032108A1 (en) * | 1997-12-19 | 1999-07-01 | Akzo Nobel N.V. | Org-5222 in the treatment of depression |
TWI327915B (en) * | 2003-06-12 | 2010-08-01 | Organon Nv | Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight |
-
2006
- 2006-04-06 EP EP06725622A patent/EP1917267B1/en active Active
- 2006-04-06 EP EP06112332A patent/EP1710245B1/en active Active
- 2006-04-06 ES ES06725622T patent/ES2318742T3/es active Active
- 2006-04-06 DE DE602006000080T patent/DE602006000080T2/de active Active
- 2006-04-06 AT AT06725622T patent/ATE418556T1/de active
- 2006-04-06 DK DK06112332T patent/DK1710245T3/da active
- 2006-04-06 MY MYPI20061554A patent/MY137969A/en unknown
- 2006-04-06 PL PL06725622T patent/PL1917267T3/pl unknown
- 2006-04-06 CA CA2603509A patent/CA2603509C/en active Active
- 2006-04-06 AU AU2006231617A patent/AU2006231617B2/en active Active
- 2006-04-06 PL PL06112332T patent/PL1710245T3/pl unknown
- 2006-04-06 SV SV2006002473A patent/SV2006002473A/es unknown
- 2006-04-06 GT GT200600135A patent/GT200600135A/es unknown
- 2006-04-06 DO DO2006P000082A patent/DOP2006000082A/es unknown
- 2006-04-06 RU RU2007141198/04A patent/RU2405786C2/ru active Protection Beyond IP Right Term
- 2006-04-06 PE PE2006000377A patent/PE20061311A1/es active IP Right Grant
- 2006-04-06 KR KR1020077025428A patent/KR101422843B1/ko active IP Right Grant
- 2006-04-06 DE DE602006004463T patent/DE602006004463D1/de active Active
- 2006-04-06 HN HN2006014095A patent/HN2006014095A/es unknown
- 2006-04-06 AR ARP060101358A patent/AR056306A1/es not_active Application Discontinuation
- 2006-04-06 RS RSP-2007/0436A patent/RS50532B/sr unknown
- 2006-04-06 PT PT06725622T patent/PT1917267E/pt unknown
- 2006-04-06 DK DK06725622T patent/DK1917267T3/da active
- 2006-04-06 AT AT06112332T patent/ATE370954T1/de active
- 2006-04-06 PT PT06112332T patent/PT1710245E/pt unknown
- 2006-04-06 BR BRPI0609741A patent/BRPI0609741A8/pt not_active IP Right Cessation
- 2006-04-06 UY UY29459A patent/UY29459A1/es not_active Application Discontinuation
- 2006-04-06 JP JP2008504776A patent/JP5058151B2/ja active Active
- 2006-04-06 WO PCT/EP2006/061408 patent/WO2006106135A1/en active Application Filing
- 2006-04-06 MX MX2007012445A patent/MX2007012445A/es active IP Right Grant
- 2006-04-06 ES ES06112332T patent/ES2293626T3/es active Active
- 2006-04-06 SI SI200630190T patent/SI1917267T1/sl unknown
- 2006-04-06 SI SI200630006T patent/SI1710245T1/sl unknown
- 2006-04-06 TW TW095112187A patent/TWI364423B/zh active
- 2006-04-06 NZ NZ562124A patent/NZ562124A/en unknown
-
2007
- 2007-09-19 HR HR20070429T patent/HRP20070429T3/xx unknown
- 2007-10-02 CY CY20071101258T patent/CY1106902T1/el unknown
- 2007-10-07 IL IL186355A patent/IL186355A/en active IP Right Grant
- 2007-10-10 NO NO20075142A patent/NO340520B1/no unknown
-
2009
- 2009-01-30 CY CY20091100111T patent/CY1108742T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0609741A8 (pt) | composto, método de preparação e uso do mesmo, composição farmacêutica, e ,método para tratar distúrbios mentais em um mamífero. | |
ECSP088413A (es) | Preparación y uso de derivados de tetrahidropirrolo[3,2-c]piridin-4-ona para el tratamiento de la obesidad, trastornos psiquiátricos y neurológicos | |
ECSP11008032A (es) | Modificacion cristalina ii de la piraclostrobina,su proceso de preparacion, su uso y las composiciones comprendidas en la modificacion ii | |
ZA201100526B (en) | Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists | |
WO2008008539A3 (en) | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor | |
WO2008079291A3 (en) | Substituted heterocycles and methods of use | |
BRPI0506858A (pt) | composto, métodos de preparação de monoidrato de gaboxadol cristalino e de anidrato de gaboxadol cristalino, composição farmacêutica, e, uso de um composto | |
EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
GEP20105054B (en) | Imidazoquinolines as lipid kinase inhibitors | |
CO6321259A2 (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis | |
TW200613305A (en) | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one | |
BRPI0519117A2 (pt) | composto, composiÇço farmacÊutica, mÉtodo para tratar neoplasmas suscetÍveis em um mamÍfero, e, uso de um composto | |
ECSP099662A (es) | Nuevos Derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
UA93044C2 (en) | urn:schemas-microsoft-com:office:smarttagsCRYSTALFORM OF ASENAPINE MALEATE | |
ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
WO2008115974A3 (en) | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors | |
CL2007003187A1 (es) | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de | |
BRPI0411673A (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
BRPI0513944A (pt) | forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição | |
TW200745137A (en) | Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | |
WO2009023539A3 (en) | Tetrahydropyridine carboxamide derivatives as trpvl antagonists | |
ATE527266T1 (de) | Herstellungsverfahren für asenapin und in diesem verfahren verwendete zwischenprodukte | |
UY28839A1 (es) | Agentes terapeuticos | |
BRPI0511424A (pt) | composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto | |
WO2009045992A3 (en) | C-met protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: MSD OSS B.V. (NL) |
|
B25A | Requested transfer of rights approved |
Owner name: ORGANON BIOSCIENCES NEDERLAND B.V. (NL) |
|
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME B.V. (NL) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.11 PUBLICADO NA RPI 2561, DE 04/02/2020. |